Experience of gemcitabine plus oxaliplatin chemotherapy in patients with advanced biliary tract carcinoma

Chemotherapy

Volumn 56, Issue 3, 2010, Pages 234-238

  Hollebecque, Antoine ^a   Bouché, Olivier ^b   Romano, Olivier ^a   Scaglia, Elodie ^b   Cattan, Stéphane ^a   Zerbib, Philippe ^a   Heurgue, Alexandra ^b   Lagarde, Stéphanie ^b   Mariette, Christophe ^a   Triboulet, Jean Pierre ^a   Pruvot, François René ^a   Hebbar, Mohamed ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b REIMS UNIVERSITY HOSPITAL   (France)

Author keywords

Biliary tract carcinoma; Cholangiocarcinoma; Gemcitabine; Oxaliplatin

Indexed keywords

GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASTHENIA; BILE DUCT CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CHOLANGITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CARCINOMA; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; TREATMENT OUTCOME;

EID: 77953342212     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316848     Document Type: Article

References (24)

1. De Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM: Biliary tract cancers. N Engl J Med 1999; 341: 1368-1378.
2. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
3. Lin MH, Chen JS, Chen HH, Su WC: A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas. Chemotherapy 2003; 49: 154-158.
4. Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, Tsipras H, Margaris H, Papastratis G, Tzima E, Papadoniou N, Karatzas G, Papalambros E: Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs 2004; 22: 193-198.
5. Kubicka S, Rudolph KL, Tietze MK, Lorenz M, Manns M: Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001; 48: 783-789.
6. Gebbia V, Giuliani F, Maiello E, Colucci G, Verderame F, Borsellino N, Mauceri G, Caruso M, Tirrito ML, Valdesi M: Treatment of inoperable and/or metastatic biliary tree carcinomas with single-agent gemcitabine or in combination with levofolinic acid and infusional fluorouracil: results of a multicenter phase II study. J Clin Oncol 2001; 19: 4089-4091.
7. Penz M, Kornek GV, Raderer M, Ulrich-Pur H, Fiebiger W, Lenauer A, Depisch D, Krauss G, Schneeweiss B, Scheithauer W: Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer. Ann Oncol 2001; 12: 183-186.
8. André T, Tournigand C, Rosmorduc O, Provent S, Maindrault-Goebel F, Avenin D, Selle F, Paye F, Hannoun L, Houry S, Gayet B, Lotz JP, de Gramont A, Louvet C: Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15: 1339-1343.
9. Harder J, Riecken B, Kummer O, Lohrmann C, Otto F, Usadel H, Geissler M, Opitz O, Henss H: Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer. Br J Cancer 2006; 95: 848-852.
10. Manzione L, Romano R, Germano D: Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience. Oncology 2007; 73: 311-315.
11. Verderame F, Russo A, Di Leo R, Badalamenti G, Santangelo D, Cicero G, Valerio MR, Gulotta G, Tomasello G, Gebbia N, Fulfaro F: Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol 2006; 17(suppl 7):68-72.
12. Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96: 896-902.
13. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
14. Andre T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W: Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer 2008; 99: 862-867.
15. Jang JS, Lim HY, Hwang IG, Song HS, Yoo N, Yoon S, Kim YH, Park E, Byun JH, Lee MA, Oh SJ, Lee KH, Kim BS, Oh SC, Kim SY, Lee SJ: Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial. Cancer Chemother Pharmacol 2010; 65: 641-647.
16. Kim HJ, Lee NS, Lee SC, Bae SB, Kim CK, Cheon YG, Kim YS, Moon JH, Cho YD, Park SH, Lee KT, Park SK, Won JH, Park HS, Hong DS: A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer. Cancer Chemother Pharmacol 2009; 64: 371-377.
17. Valle JW, Wasan HS, Palmer DD, Cunningham D, Anthoney DA, Maraveyas A, Hughes SK, Roughton M, Bridgewater JA: Gemcitabine with or without cisplatin in patients with advanced or metastatic biliary tract cancer (ABC): results of a multicenter, randomized phase III trial (the UK ABC-02 trial). Proc Am Soc Clin Oncol 2009; 221s:abstr 4503.
18. Saleh S, Ain-Shoka AA, El-Demerdash E, Khalef MM: Protective effects of the angiotensin II receptor blocker losartan on cisplatin-induced kidney injury. Chemotherapy 2009; 55: 399-406.
19. Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R, Baka S, Maraveyas A, Corrie P, Falk S, Gollins S, Lofts F, Evans L, Meyer T, Anthoney A, Iveson T, Highley M, Osborne R, Bridgewater J: Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study-The UK ABC-01 Study. Br J Cancer 2009; 101: 621-627.
20. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E: Supraadditive effect of 2- ,2-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44: 117-123.
21. Moschidis A, Papageorgiou A, Atmatzidis K, Tsalis K, Moschidis E, Livanis J, Chrysogelou E, Mourelatos D, Tsavdaridis D, Harlaftis N: Synergistic antitumor activity of oxaliplatin in combination with gemcitabine in pancreatic tumor-bearing mice. Chemotherapy 2007; 53: 153-159.
22. Sirica AE: Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma. World J Gastroenterol 2008; 14: 7033-7058.
23. Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW, Gores GJ: Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 2004; 41: 808-814.
24. Malka D, Trarbach T, Fartoux L, Mendiboure J, de la Fouchardière F, Viret F, Assenat E, Boucher E, Rosmorduc O, Greten T: A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial. Proc Am Soc Clin Oncol 2009; 206s:abstr 4520.